Hey, life science startups: Looks like Massachusetts investment firm BioVentures is raising a new venture fund – and has raised about $20 million of a potential $100 million pot, according to a regulatory filing.
Historically, the fund’s been focused heavily on medtech investments, with dollars also poured into therapeutics and diagnostics. No reason to assume otherwise with this fund. Some of its portfolio companies include Enanta Pharmaceuticals, Claros Diagnostics (acquired by OPKO Pharmaceuticals in 2011 for $49 million), and Hydra Biosciences.
